Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Stomach Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Glioblastoma 1Drug-Related Side Effects and Adverse Reactions 1Depression 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Anxiety Disorders 1All Solid Tumors 1

Interventions

Dexamethasone 33Cyclophosphamide 31fludarabine 19venetoclax 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Pharmaceutical Preparations × Clear all
NCT06208657 2026-01-28

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Australian & New Zealand Children's Haematology/Oncology Group

Phase 1/2 Recruiting
90 enrolled
CNSLymphoid

Lymphoma, Neoplasms, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡